Emobot logo
FR
EN

Advanced AI for continuous mood disorders diagnosis & therapy

Empowering Patients, enhancing Diagnosis & Care, and elevating Pharma Standards

Discover ->
Why Emobot ?

An ever-widening gap between the increase in mood disorders and the lack of global medical resources and drug efficacy

Major Depressive Disorder (MDD) is a massive chronic disease,
with paper questionnaire remaining the Gold Standard

show_chart
Increase in mood disorders
Increase in depressive/anxious patients
18.5% of Americans people suffer from Depression (12.5% in France) and 11% of Americans take antidepressants (AD).
More than 320M worldwide.
Treatment resistance and chronic depression
1/3 patients are Treatment Resistants(TRD), and 1/2 have chronic MDD
show_chart
Lack of global medical resources
Medical Desertification
Only 60k psychiatrists in the USA: that is 1 psychiatrist for 1000 patients‍
Hospital capabilities and availability
- Several months before a consultation & Doctors have not enough time for each patient.
- Finding the right treatment is a never ending fight.
show_chart
Limited drug development because of limited gold standards endpoints
Risk in trials

Pharma and Biotechs risk $10-250M in each phase II/III trials.

Limited endpoints
- Pharma and Biotechs have no objective nor continuous endpoint or device to measure the efficacy of their drugs.
- They are limited to twice-a-month subjective information about the patient’s disorder in their trials

USA MDD overall cost (2023):

$382 Billion, including $150 Billion direct health costs.

Today, unlike all other health disciplines, there is still no automatic solution for diagnosing or helping to diagnose mood disorders.

Doctors rely on clinical observation and psychiatric questionnaires developed according to the controversial DSM-IV/DSM-V classification.
Discover EmoDTx and EmoCare
The 1st medical devices ever created for mood disorders diagnosis and therapy based on automatic mood monitoring.
Our product

One product as both a Diagnostic tool: EmoCare
and a Therapy: EmoDTx

We’ve developed the first thermometer for depressive disorders.

Cognitive Behavioral Therapies with Self-
Mood monitoring
as a Diagnostic aid, Treatment aid & Endpoint
EmoDTx
EmoCare
The technology

Thanks to our emotional signals, we can continuously monitor mood and other symptoms of mood disorders.

How it works.

Using Artificial Intelligence, we analyze the evolution of mood disorders over time by passively studying people's emotional behavior, via their facial expressions, as well as their voice.
‍
EMOBOT, with its partner the AIMAC laboratory (CentraleSupélec, IETR, CNRS) headed by co-founder Renaud Séguier, is developing algorithms, signals and digital biomarkers to automatically estimate the severity of disorders and their evolution in patients.

Our algorithms create an emotional heat map that summarizes a person's "emotional tone" throughout the day by accumulating the emotions detected. For example, one map may show predominantly neutral emotion and a diversity of emotions for a person with good emotional tone, while another may show low emotional intensity and predominantly neutral emotions for a person with low emotional tone.

Visualising the mood of a bipolar patient

Month 1
Month 2
Month 3
Value proposition

Revolutionizing Mental Health: empowering Patients, enhancing Diagnosis & Care, and elevating Pharma Standards

Interested?
Reach out to us

Contact us by mailContact our CEO on LinkedIn
Continuous monitoring of mood disorders
by Artificial Intelligence

Legal

Legal noticeImage credits

Follow us

EmailLinkedInTwitterYoutubePress kit

General

HomeAbout us